Previous 10 | Next 10 |
Flexion Therapeutics (FLXN) reported a 22% jump in first-quarter sales, driven by strong demand for its knee pain drug ZILRETTA.The company said sales for ZILRETTA increased to $24.6M in the quarter, up from $20.1M in the prior-year period. The company's topline, however, missed analysts...
Flexion Therapeutics (FLXN): Q1 GAAP EPS of -$0.57 misses by $0.06.Revenue of $24.59M (+22.2% Y/Y) misses by $0.21M.“The first quarter of 2021 was marked by solid ZILRETTA sales and important progress with both FX201 and FX301, our exciting investigational drug candidates,” said...
Flexion reported ZILRETTA ® (triamcinolone acetonide extended-release injectable suspension) net sales of $24.6 million David Arkowitz, CFO, stepping down effective May 31,2021, and will be succeeded by Fred Driscoll New data presente...
BURLINGTON, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, May 12, 2021. A live webcast of the conference call can...
Last month, management guided Zilretta revenue to grow 50% to $120-130 million. Huge runway with under 5% market penetration into osteoarthritis knee pain indication. Despite growing revenue nearly 20% last year during the pandemic and guiding to 50% this year, shares trade at a 52-we...
Flexion Therapeutics (FLXN) reports preliminary data from a Phase 1 single ascending dose ((SAD)) of FX201, an intra-articular gene therapy candidate for osteoarthritis ((OA)). FX201 was generally well-tolerated in the initial low-dose cohort.Two patients had self-limited Grade 2 in...
Findings from a Phase 1 single ascending dose trial indicate the low dose of FX201, an intra-articular gene therapy candidate for osteoarthritis (OA), was generally well-tolerated Two of five patients (40%) treated with FX201 in the low-dose, single ascending dose cohort reported subs...
Image source: The Motley Fool. Flexion Therapeutics Inc (NASDAQ: FLXN) Q1 2021 Earnings Call Apr 13, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Flexion Therapeutics Inc (FLXN) Q1 2021 Earnings Call Transcript ...
Gainers: [[PFMT]] +13.7%. [[MVIS]] +4.3%. [[CLSD]] +4.2%. [[FLXN]] +3.7%. [[FOLD]] +3.7%.Losers: [[STSA]] -9.9%. [[CNTG]] -7.9%. [[XELB]] -6.2%. [[CLAR]] -5.9%. [[DISCK]] -5.2%. For further details see: PFMT, MVIS, STSA and XELB among after-hours movers
Flexion Therapeutics (FLXN) trades 3.6% higher after hours on reporting prelim ZILRETTA net sales of ~$24.6M for the quarter ended Mar.31, 2021."“While the impacts of the COVID-19 pandemic continue to affect patient flows, barring any unforeseen resurgence or outbre...
News, Short Squeeze, Breakout and More Instantly...
Flexion Therapeutics Inc. Company Name:
FLXN Stock Symbol:
NASDAQ Market:
Flexion Therapeutics Inc. Website:
-- Adds highly complementary ZILRETTA ® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc...